MicroStrategy
MSTR
NVIDIA
NVDA
Salesforce
CRM
Adobe
ADBE
Meritage Homes
MTH
US Stock MarketDetailed Quotes
APLS Apellis Pharmaceuticals
- 33.825
- +0.685+2.07%
Trading Dec 20 12:09 ET
4.21BMarket Cap-16.66P/E (TTM)
33.980High32.900Low607.57KVolume33.160Open33.140Pre Close20.25MTurnover0.72%Turnover RatioLossP/E (Static)124.39MShares73.80052wk High17.75P/B2.85BFloat Cap24.34052wk Low--Dividend TTM84.36MShs Float94.750Historical High--Div YieldTTM3.26%Amplitude11.450Historical Low33.330Avg Price1Lot Size
Apellis Pharmaceuticals Key Stats
EPS
According to the latest financial report of Apellis Pharmaceuticals, the latest earnings per share (TTM) for the company is -0.46. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Apellis Pharmaceuticals's free cash flow? The latest report shows it as 34.10M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Apellis Pharmaceuticals shows that the company's current ratio is 4.36, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Apellis Pharmaceuticals, the quick ratio is 3.56, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Apellis Pharmaceuticals? The latest ROE figure is -22.91%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Apellis Pharmaceuticals, the total asset return on investment (ROA) is -6.36%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Apellis Pharmaceuticals's latest financial report to see how their gross margin is doing - currently at 82.95%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Apellis Pharmaceuticals, the net profit margin is -29.19%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
